Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues

Nature Nanotechnology

Volumn 11, Issue 11, 2016, Pages 986-994

  Zanganeh, Saeid ^a   Hutter, Gregor ^a,b   Spitler, Ryan ^a   Lenkov, Olga ^a   Mahmoudi, Morteza ^a   Shaw, Aubie ^c   Pajarinen, Jukka Sakari ^b   Nejadnik, Hossein ^a   Goodman, Stuart ^b   Moseley, Michael ^a   Coussens, Lisa Marie ^c   Daldrup Link, Heike Elisabeth ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; FLOW CYTOMETRY; HISTOLOGY; IRON OXIDES; MACROPHAGES; MAGNETIC RESONANCE IMAGING; MAMMALS; METAL NANOPARTICLES; NANOMAGNETICS; PATHOLOGY; TUMORS;

ADENOCARCINOMA CELLS; CANCER IMMUNOTHERAPY; FLUORESCENCE ACTIVATED CELL SORTING; FOOD AND DRUG ADMINISTRATION; INHIBITED GROWTH; IRON OXIDE NANOPARTICLE; IRON SUPPLEMENTS; THERAPEUTIC EFFECTS;

DRUG DELIVERY;

CARBOXYMETHYLDEXTRAN; CASPASE 3; FERUMOXYTOL; MESSENGER RNA; TUMOR NECROSIS FACTOR; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; ANTINEOPLASTIC AGENT; MAGNETITE; METAL NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER TISSUE; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; LUNG ALVEOLUS MACROPHAGE; LUNG METASTASIS; MAMMARY GLAND FAT; MOUSE; NONHUMAN; PHENOTYPE; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; THERAPY EFFECT; ANIMAL; CELL POLARITY; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL MAMMARY NEOPLASM; HUMAN; INBRED MOUSE STRAIN; INFLAMMATION; LIVER TUMOR; LUNG TUMOR; MACROPHAGE; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROCEDURES; SECONDARY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL POLARITY; FEMALE; FERROSOFERRIC OXIDE; HUMANS; INFLAMMATION; LIVER NEOPLASMS; LUNG NEOPLASMS; MACROPHAGES; MAMMARY NEOPLASMS, EXPERIMENTAL; METAL NANOPARTICLES; MICE, INBRED NOD; MICE, INBRED STRAINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84988694000     PISSN: 17483387     EISSN: 17483395     Source Type: Journal    
DOI: 10.1038/nnano.2016.168     Document Type: Article

References (42)

1. Corot C. Robert P. Idee J. M. & Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv. Drug Deliv. Rev. 58 1471-1504 (2006).
2. Daldrup-Li nk H. E. et al. MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin. Cancer Res. 17 5695-5704 (2011).
3. Klenk C. et al. Ionising radiation-free whole-body MRI versus 18F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective non-randomised single-centre study. Lancet Oncol. 15 275-285 (2014).
4. Ansari C. et al. Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy. Small 10 566-57 5 (2014).
5. Neuwelt E. A. et al. The potential of ferumoxytol nanoparticle magnetic resonance imaging perfusion and angiography in central nervous system malignancy: a pilot study. Neurosurgery 60 6 01-611 (2007).
6. Daldrup-Link H. Coussens L. M. MR imaging of tumor-associated macrophages Oncoimmunology 1 507-509 2012).
7. Vinogradov S. Warren G. & Wei X. Macrophages associated with tumors as potential targets and therapeutic intermediates. Nanomedicine 9 695-707 (2014).
8. Miller M. A. et al. Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug. Nat. Commun. 6 8692 (2015).
9. Weissleder R. Nahrendorf M. & Pittet M. J. Imaging macrophages with nanoparticles. Nat. Mater. 13 125-138 (2014).
10. Li C. A targeted approach to cancer imaging and therapy. Nat. Mater. 13 110-115 (2014).
11. Futterer S. Andrusenko I. Kolb U. Hofmeister W. & Langguth P. Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD). J. Pharm. Bi omed. Anal. 86 151-160 (2013).
12. Ittrich H. Peldschus K. Raabe N. Kaul M. & Adam G. Superparamagnetic iron oxide nanoparticles in biomedicine: applications and developments in diagnostics and th erapy. RoFo 185 1149-1166 (2013).
13. Richards J. M. et al. In vivo mononuclear cell tracking using superparamagnetic particles of iron oxide: feasibility and safety in humans. Circ. Cardiovasc. Imaging 5 509-517 (2012).
14. Warheit D. B. & Hartsky M. A. Role of alveolar macrophage chemotaxis and phagocytosis in pulmonary clearance responses to inhaled particles: comparisons among rodent species. Microsc. Res. Tech 26 412-422 (1993).
15. Sindrilaru A. et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J. Clin. Invest. 121 985-997 (2011).
16. Wodarz D. & Anton-Culver H. Dynamical interactions between multiple cancers. Cell Cycle 4 764-771 (2005).
17. Nejadnik H. et al. Somatic differentiation and MR imaging of magnetically labeled human embryonic stem cells. Cell Transplant. 21 2555-2567 (2012).
18. Jahchan N. S. et al. A drug repositioning approach iden tifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov. 3 1364-1377 (2013).
19. Lu M. Cohen M. H. Rieves D. & Pazdur R. FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am. J. Hematol. 85 315-319 (2010).
20. Choi J. Y. et al. Iron intake oxidative stress-related genes (MnSOD and MPO) and prostate cancer risk in CARET cohort. Carcinogenesis 29 964-970 (2008).
21. Poljak-Blazi M. et al. Effect of ferric ions on reactive oxygen species formation cervical cancer cell lines growth and E6/E7 oncogene expression. Toxicol. In Vitro 25 160-166 (2011).
22. Crowe W. E. Maglova L. M. Ponka P. & Russell J. M. Human cytomegalovirus-induced host cell enlargement i s iron dependent. Am. J. Physiol. Cell Physiol. 287 C1023-C1030 (2004).
23. Petersen D. R. Alcohol iron-associated oxidative stress and cancer. Alcohol 35 243-249 (2005).
24. Nie G. Chen G. Sheftel A. D. Pantopoulos K. & Ponka P. In vivo tumor growth is inhibited by cytosolic iron deprivation caused by the expression of mitochondrial ferritin. Blood 108 2428-2434 (20 06).
25. Knobel Y. Glei M. Osswald K. & Pool-Zobel B. L. Ferric iron increases ROS formation modulates cell growth and enhances genotoxic damage by 4-hydroxynonenal in human colon tumor cells. Toxicol. In Vitro 20 793-800 (2006).
26. Basel M. T. et al. Cell-delivered magnetic nanoparticles caused hyperthermia-mediated increased survival in a murine pancreatic cancer model. Int. J. Nanomedicine 7 297-306 (2012).
27. Chung T. H. et al. Iron oxide nanoparticle-induced epidermal growth factor receptor expression in human stem cells for tumor therapy. ACS Nano 5 9807-9816 (2011).
28. Foy S. P. & Labhasetwar V. Oh the irony: iron as a cancer cause or cure? Biomaterials 32 9155-9158 (2011).
29. Reinisch W. Staun M. Bhandari S. & Munoz M. State of the iron: how to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease. J. Crohns Colitis 7 429-440 (201 3).
30. Lunov O. et al. Lysosomal degradation of the carboxydextran shell of coated superparamagnetic iron oxide nanoparticles and the fate of professional phagocytes. Biomaterials 31 9015-9022 (2010).
31. Gupta A. K. & Wells S. Surface-modified superparamagnetic nanoparticles for drug delivery: preparation characterization and cytotoxicity studies. IEEE Trans. Nanobioscience 3 66-73 (20 04).
32. Mou W. et al. Expression of Sox2 in breast cancer cells promotes the recruitment of M2 macrophages to tumor microenvironment. Cancer Lett. 358 115-123 (2015).
33. Becker M. Muller C. B. De Bastiani M. A. & Klamt F. The prognostic impact of tumor-associated macrophages and intra-tumoral apoptosis in non-small cell lung cancer. Histol. Histopathol. 29 21-31 (2014).
34. Laskar A. Eilertsen J. Li W. & Yuan X. M. SPION primes THP1 derived M2 macrophages towards M1-like macrophages. Biochem. Biophys. Res. Commun. 441 737-742 (2013).
35. Solinas G . Germano G. Mantovani A. & Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol. 86 1065-1073 (2009).
36. Franklin R. A. et al. The cellular and molecular origin of tumor-associated macrophages. Science 344 921-925 (2014).
37. Edris B. et al. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc. Natl Acad. Sci. USA 109 6656-6661 (2012).
38. Shiao S. L. et al. TH2-polarized CD4+ T cells and macrophages limit efficacy of radiotherapy. Cancer Immunol. Res. 3 518-525 (2015).
39. Hadjipanayis C. G. et al. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res. 70 6303-6312 (2010).
40. Thorek D. L. et al. Non-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle. Nat. Commun. 5 3097 (2014).
41. Rosner M. H. & Auerbach M. Ferumoxytol for the treatment of iron deficiency. Expert Rev. Hematol. 4 399-406 (2011).
42. Cheng K. et al. Magnetic antibody-linked nanomatchmakers for therapeutic cell targeting. Nat. Commun. 5 4880 (2014).